AbbVie Inc. (ABBV)
| Market Cap | 354.14B |
| Revenue (ttm) | 58.33B |
| Net Income (ttm) | 3.72B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.10 |
| PE Ratio | 95.45 |
| Forward PE | 15.23 |
| Dividend | $6.56 (3.27%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 1,053,144 |
| Open | 199.76 |
| Previous Close | 198.64 |
| Day's Range | 199.21 - 201.52 |
| 52-Week Range | 163.81 - 218.66 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 216.10 (+7.8%) |
| Earnings Date | Jul 31, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $216.1, which is an increase of 7.80% from the latest price.
News
My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys
July saw strong market gains, especially in tech, but finding bargains is tough as indices approach all-time highs. I focused July investments on high-yield BDCs like OBDC, MFIC, and BXSL, maintaining...
AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition
AbbVie Inc.'s Q2 2025 results highlight Skyrizi and Rinvoq's dominance, replacing Humira and driving impressive revenue growth, with both drugs exceeding expectations. The company's aggressive neurosc...
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced commi...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...
Get Ready, JUVÉDERM® Day is Calling!
Allergan Aesthetics Celebrates Third Annual JUVÉDERM® Day with BOGO Gift Cards and $10,000 Sweepstakes Join Allē Today to Take Advantage of Limited-Time Offers, While Supplies Last IRVINE, Calif. , Au...
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
Nine women from across the U.S. share their personal experiences with breast augmentation and reconstruction with Natrelle® – celebrating confidence, self-expression, and restoration. IRVINE, Calif.
The Big 3: ABBV, ETSY, VRT
Mike Shorr (@ProsperTradingAcademy) walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a c...
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
On Thursday, AbbVie Inc. ABBV reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.
5 Dividend Stocks With Solid Returns And More Growth Ahead
Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ET Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Jeffrey Ryan Stewart - Executive VP...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
AbbVie Stock Pops After Earnings Beat and Guidance Raised
Second quarter EPS came in at $2.97 on revenue of $15.4 billion, beating analysts expectations.
AbbVie lifts annual profit forecast on strong demand for newer immunology drugs
AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq.
AbbVie Reports Second-Quarter 2025 Financial Results
Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.4...
AbbVie in talks to acquire Gilgamesh Pharmaceuticals
Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, citing peopl...
Sell AbbVie Stock Ahead of Its Upcoming Earnings?
AbbVie (NYSE:ABBV) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, understanding historical stock performance around earnings announcements can be a v...
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with ...
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed stati...